Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

LNG Energy Group Corp. V.LNGE

Alternate Symbol(s):  V.LNGE.W | LNGNF

LNG Energy Group Corp is a Canada-based company, which is focused on the acquisition and development of natural gas production and exploration assets in Latin America. The Company’s assets include Sinu-San Jacinto-1(SSJN-1), Valle Inferior del Magdelana-41 (VIM-41), Valle Inferior del Magdalena-42 (VIM-42) and Sinu-San Jacinto 3-1(SSJN 3-1). The Company has a 50% working interest in SSJN-1, VIM-42 and SSJN 3-1. The Company has a 100% working interest in VIM-41. SSJN-1 covers approximately 226,000 acres. SSJN 3-1 covers approximately 83,000 acres. VIM-41 includes 93 billion cubic feet equivalent (BCFE) of net 3P reserves. It covers approximately 172,000 acres. VIM-42 includes 405 billion cubic feet (BCF) of prospective resource and covers approximately 228,000 acres.


TSXV:LNGE - Post by User

Post by Investmentwinon Feb 01, 2022 7:10pm
214 Views
Post# 34387387

Psychedelic Industry 2022 The Big Turnaround

Psychedelic Industry 2022 The Big Turnaround

It was a wild 2021. We had NASDAQ uplists and multi-billion dollar IPOs. And despite some pretty extreme market fluctuations, the psychedelic medicine industry has managed to cement itself as a legitimate biotech sector worthy of investor confidence.

While 2022 hasn’t yet given us the market turnaround we had hoped for, the forthcoming 12 months will be filled with clinical trial news and significant milestones, and the current price pullback may present interesting opportunities for investors.

<< Previous
Bullboard Posts
Next >>